AxoGen, Inc. (AXGN)

NASDAQ: AXGN · IEX Real-Time Price · USD
7.81
+0.04 (0.51%)
Mar 28, 2024, 9:37 AM EDT - Market open

Company Description

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.

The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.

The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons.

AxoGen, Inc. is headquartered in Alachua, Florida.

AxoGen, Inc.
AxoGen logo
Country United States
Industry Medical Devices
Sector Healthcare
Employees 426
CEO Ms. Karen Zaderej

Contact Details

Address:
13631 Progress Blvd., Suite 400
Alachua, Florida 32615
United States
Phone (386) 462-6817
Website axogeninc.com

Stock Details

Ticker Symbol AXGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000805928
CUSIP Number 05463X106
ISIN Number US05463X1063
Employer ID 41-1301878
SIC Code 3845

Key Executives

Name Position
Karen Zaderej Chairman, President and Chief Executive Officer
Michael Donovan Vice President of Operations
Angelo G. Scopelianos Ph.D. Chief Research and Development Officer
Nir Naor C.F.A., CPA, L.L.M., M.B.A. Chief Financial Officer
Harold D. Tamayo Vice President of Finance and Investor Relations
Marc A. Began Executive Vice President, General Counsel and Chief Compliance Officer
Doris Quackenbush Vice President of Sales
Jens Schroeder Kemp Chief Marketing Officer
Erick DeVinney Chief Innovation Officer
Dr. Ivica Ducic M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 13, 2024 EFFECT Notice of Effectiveness
Mar 8, 2024 8-K Current Report
Mar 7, 2024 144 Filing
Mar 7, 2024 144 Filing
Mar 6, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 6, 2024 S-3 Registration statement under Securities Act of 1933
Mar 6, 2024 POS AM Post-Effective amendments for registration statement
Mar 5, 2024 8-K Current Report
Mar 5, 2024 10-K Annual Report
Mar 5, 2024 8-K Current Report